SomnoMed Limited (SOMNF)
| Market Cap | 54.56M -47.8% |
| Revenue (ttm) | 79.23M +2.7% |
| Net Income | -1.83M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 17.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 0.4479 |
| Previous Close | 0.5149 |
| Day's Range | 0.4479 - 0.4479 |
| 52-Week Range | 0.4200 - 0.5149 |
| Beta | 0.80 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About SomnoMed
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. The company offers SomnoDent, such as SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, herbst advance, and SomnoDent Fusion for the treatment of obstructive sleep apnea. It also provides SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patien... [Read more]
Financial Performance
In fiscal year 2026, SomnoMed's revenue was 114.53 million, an increase of 2.73% compared to the previous year's 111.49 million. Losses were -2.65 million, -23.32% less than in 2025.
Financial numbers in AUD Financial StatementsNews
SomnoMed Earnings Call Transcript: H2 2026
FY 2026 saw strong EBITDA growth, improved margins, and expanded manufacturing capacity, with North America leading revenue gains. Strategic focus is on product innovation, Virtus rollout, and addressing European reimbursement challenges, with high single-digit revenue growth targeted for FY 2027.
SomnoMed Annual report: H2 2026
SomnoMed has published its H2 2026 annual report on August 27, 2026.
SomnoMed Earnings release: H2 2026
SomnoMed released its H2 2026 earnings on August 27, 2026, summarizing the period's financial results.
SomnoMed Slides: H2 2026
SomnoMed has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 27, 2026.
SomnoMed Earnings Call Transcript: H1 2026
Revenue grew 13% to AUD 60.7 million with EBITDA up 35% and stable gross margins. Europe and North America drove growth, while APAC softened. Guidance for FY 2026 is reaffirmed, with continued investment in manufacturing, R&D, and innovation, notably RestAssure.
SomnoMed Quarterly report: H1 2026
SomnoMed has published its H1 2026 quarterly earnings report on February 26, 2026.
SomnoMed Slides: H1 2026
SomnoMed has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 26, 2026.
SomnoMed Earnings release: H1 2026
SomnoMed released its H1 2026 earnings on February 26, 2026, summarizing the period's financial results.
SomnoMed Slides: FY 2025
SomnoMed has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 26, 2025.
SomnoMed Earnings release: Q1 2026
SomnoMed released its Q1 2026 earnings on October 29, 2025, summarizing the period's financial results.
SomnoMed Slides: Investor Presentation
SomnoMed has posted slides in relation to its latest quarterly earnings report, which was published on October 20, 2025.